Lucid Diagnostics registers 36.98M shares for resale by selling stockholders; company gets no proceeds

Filed June 3, 2025 · ~1 min read

Key Changes

• high

  The prospectus covers up to 36,975,000 shares of common stock offered by selling stockholders, not by Lucid Diagnostics.

  The Offering verify on EDGAR →
• high

  Lucid Diagnostics will not receive any proceeds from these sales; all proceeds go to the selling stockholders.

  The Offering verify on EDGAR →
• medium

  The shares are issuable upon conversion of $21.975 million of senior secured convertible notes sold in November 2024.

  The Offering verify on EDGAR →